sintilimab + tislelizumab

This entry refers to the investigator's choice of anti-PD-1 therapy, specifically either **sintilimab** or **tislelizumab**, used in the control arm of clinical trials for advanced gastric or gastroesophageal junction (GEJ) cancer. Sintilimab (Tyvyt) and tislelizumab (Tevimbra) are both humanized monoclonal antibodies that target the programmed cell death protein 1 (PD-1) receptor. By blocking the interaction between PD-1 and its ligands (PD-L1 and PD-L2), these agents enhance T-cell mediated anti-tumor immune responses. In the context of the referenced Phase III trial (NCT06473103), they are administered in combination with CAPOX (capecitabine and oxaliplatin) as a standard-of-care comparator against retlirafusp alfa.

Other names

IBI308IBI-308IBI 308BGB-A317BGB-A-317BGB-A 317